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Th e standard treatment for acute respiratory failure in 
critically ill patients has been based on oxygen therapy 
and invasive mechanical ventilation with endotracheal 
intubation. In addition, non-invasive mechanical ventila-
tion (NIV) has proved an excellent technique, avoiding 
the need for intubation and improving outcome in 
selected patients with acute cardiogenic pulmonary 
edema, exacerbation of chronic obstructive pulmonary 
disease (COPD), and acute hypoxemic respiratory failure 
[1-4]. Conversely to invasive mechanical ventilation, NIV 
can also be used outside the intensive care unit [5]. 
However, NIV can fail because of either the patient’s 
underlying conditions or multiple technical causes. 
Despite improvements in the oro-nasal mask’s charac-
teristics, intolerance to the device represents a frequent 
cause of failure [6]; thus, the interface is fundamental in 
the care of patients. One possible alternative to the face 
mask could be the helmet, especially for long-term use 
(Figure  1). Although the facial mask is still the most 
commonly used interface in up to 60% of cases, in some 
European countries (such as Italy), the helmet is widely 
employed for patients with acute hypo xemic respiratory 
failure and acute cardiogenic pulmo nary edema [6].
Th e aim of this clinical review is to summarize the 
main physiological and clinical studies assessing the 
eﬃ  cacy (arterial oxygenation, intubation rate, outcome 
and tolerance) of NIV delivered with the helmet.
Methods
Search strategy
A computerized search of MEDLINE/PubMed (January 
2000 to May 2012) and EMBASE (January 2000 to May 
2012) for articles in English, Spanish and Italian was 
conducted, limiting the search to retrospective, pros-
pective, non-randomized and randomized trials. Th e 
keywords ‘noninvasive ventilation’, ‘helmet’ and ‘interface’ 
were combined with any of the terms ‘chronic obstructive 
pulmonary disease’, ‘hypoxemic acute respiratory failure’, 
‘continuous positive airway pressure’, ‘bi-level airway 
pressure’ and ‘pressure support ventilation’. Th e bio gra-
phies of all selected articles were hand searched for addi-
tional relevant articles.
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at the interface. The helmet could be an alternative 
interface compared to face mask to improve NIV 
success. We performed a clinical review to investigate 
the main physiological and clinical studies assessing 
the effi  cacy and related issues of NIV delivered with a 
helmet. A computerized search strategy of MEDLINE/
PubMed (January 2000 to May 2012) and EMBASE 
(January 2000 to May 2012) was conducted limiting 
the search to retrospective, prospective, non-
randomized and randomized trials. We analyzed 152 
studies from which 33 were selected, 12 physiological 
and 21 clinical (879 patients). The physiological studies 
showed that NIV with helmet could predispose to 
CO2 rebreathing and increase the patients’ ventilator 
asynchrony. The main indications for NIV were acute 
cardiogenic pulmonary edema, hypoxemic acute 
respiratory failure (community-acquired pneumonia, 
postoperative and immunocompromised patients) 
and hypercapnic acute respiratory failure. In 9 of the 
21 studies the helmet was compared to a face mask 
during either continous positive airway pressure 
or pressure support ventilation. In eight studies 
oxygenation was similar in the two groups, while the 
intubation rate was similar in four and lower in three 
studies for the helmet group compared to face mask 
group. The outcome was similar in six studies. The 
tolerance was better with the helmet in six of the 
studies. Although these data are limited, NIV delivered 
by helmet could be a safe alternative to the face mask 
in patients with acute respiratory failure.
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Five international experts participated and conducted this 
analysis (AE, PP, MC, RC, DC) and classiﬁ ed the results into 
two major groups: physiological and clinical studies.
Results
In the text the data are expressed as mean  ±  standard 
deviation. We analyzed 152 studies from which 33 were 
selected for this clinical review. Twelve of these were 
physiological studies, performed in healthy subjects, and 
21 were clinical studies, performed in patients with acute 
respiratory failure (Figure 2). Tables 1 and 2 summarize 
the main results.
Physiological studies
Carbon dioxide rebreathing
Compared to the face mask the helmet, due to its larger 
internal volume, might facilitate carbon dioxide (CO2) 
rebreathing. Patroniti and colleagues [7] found that, with 
continuous ﬂ ow continuous positive airway pressure 
(CPAP) and a gas ﬂ ow from 20 to 60  L/minute and 
positive end-expiratory pressure (PEEP) from 0 to 
15 cmH2O, the inspiratory CO2 concentration was always 
higher with the helmet than with the face mask 
(3.1 ± 0.15 versus 0.8 ± 0.3 mmHg, P < 0.01). Increasing 
the gas ﬂ ow rate signiﬁ cantly lowered the inspiratory 
CO2 concentration.
Similarly, Taccone and colleagues [8] observed that the 
CO2 concentration was similar between a continuous low 
ﬂ ow CPAP (10 L/minute) and CPAP delivered by a mech-
anical ventilator (13.7 ± 6.6 versus 12.4 ± 3.2 mmHg). In 
addition, reducing the size of the helmet did not prevent 
CO2 rebreathing, suggesting that the CO2 rebreathing 
primarly depends on the fresh gas passing through the 
helmet and the amount of CO2 produced by the patient.
Among the commercially available helmets, CO2 re-
breathing was lower than 5  mmHg and not diﬀ erent 
during continuous high ﬂ ow CPAP [9]. An antisuﬀ ocation 
valve, which allows room air to enter the helmet during 
any interruption of gas ﬂ ow, limited the CO2 rebreathing 
but not the loss of external PEEP [9]. In a subsequent 
study, Milan and colleagues [10], testing three commer-
cially available helmets supplied with antisuﬀ ocation 
valves, found that the helmet with the largest valve had 
lower CO2 rebreathing but a greater reduction in 
oxygena tion in case of interruption of the gas ﬂ ow.
Costa and colleagues [11] tested the helmet at diﬀ erent 
PSV and PEEP combinations and did not ﬁ nd any 
changes in CO2 rebreathing, which ranged from 5.2 ± 3.1 
to 6.7  ±  3.3  mmHg. However, during PSV of 5, 10 and 
15 cmH2O with an increased respiratory muscle load, the 
helmet was always associated with more CO2 rebreathing 
independent of the level of pressure support compared to 
the face mask (4.3 ± 0.5 versus 0.0 ± 0.0 mmHg, 3.5 ± 1.0 
versus 0.4  ±  0.4  mmHg and 4.4  ±  1.3  mmHg versus 
0.5 ± 0.6 mmHg; P < 0.0001) [12].
Racca and colleagues [13] evaluated if an intentional 
leak at the helmet expiratory port during PSV, by 
increasing the ﬂ ow through the helmet, could ameliorate 
the CO2 rebreathing. NIV and CPAP were delivered using 
closed and open circuit ventilators equipped with a 
plateau valve positioned at the helmet’s expiratory port. 
CO2 rebreathing was signiﬁ cantly lower with the open-
circuit ventilators. However, inspiratory pressure assis-
tance signiﬁ cantly dropped with these open-circuit 
ventilators, casting doubt on the choice of the optimal 
helmet ventilation setup.
Breathing pattern, inspiratory eff ort and comfort
Besides the larger internal volume that aﬀ ects CO2 
rebreathing, the higher compliance of the helmet might 
delay ventilator assistance and may promote patient-
ventilator asynchrony.
Figure 1. Non-invasive ventilation and helmet in use on a patient with acute respiratory syndrome in the ICU.
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Chiumello and colleagues [14] evaluated the breathing 
pattern and work of breathing (WOB) with helmet and 
face masks during continuous ﬂ ow CPAP, mechanical 
ventilator CPAP and PSV. During continuous ﬂ ow CPAP, 
mechanical ventilator CPAP and PSV there was no 
diﬀ erence in breathing pattern and WOB; on the con-
trary, during PSV the face mask signiﬁ cantly reduced the 
WOB compared to the helmet. Th e helmet requires a 
signiﬁ cant portion of the ventilator pressure in the initial 
phase of inspiration to pressurize its inner volume and 
not the patient, resulting in less assistance (that is, it 
takes a longer time to reach the required level of pressure 
support).
In a subsequent study Costa and colleagues [11], raising 
the level of pressure support from 5 to 15 cmH2O, found 
that the respiratory rate and inspiratory eﬀ ort with the 
helmet progressively decreased and tidal volume increased 
compared to spontaneous breathing. Th e highest level of 
pressure support (15 cmH2O) signiﬁ cantly increased the 
discomfort.
Racca and colleagues [12] compared the helmet and 
face mask during PSV with normal and high respiratory 
muscle load to mimic dyspneic patients. With normal 
muscle load the breathing pattern and inspiratory eﬀ ort 
was not diﬀ erent with helmet and face mask, but with 
high respiratory muscle load the inspiratory eﬀ ort was 
signiﬁ cantly higher with the helmet than with the face 
mask.
Helmet devices may predispose to auto-cycled pheno-
mena. Its elastic properties thus predispose to ﬂ ow 
variations not tracked by eﬀ ective inspiratory or 
expiratory eﬀ orts. Autocycled breathing was more 
common with helmet ventilation - on average double that 
with face mask ventilation [12]. Th e dyspnea score was 
signiﬁ cantly higher with high respiratory muscle load 
with helmet compared to face mask ventilation [12].
Patient ventilator synchrony
PSV, the most commonly used ventilatory support during 
NIV, is regulated by pneumatic triggering based on ﬂ ow 
criteria. To improve patient ventilator synchrony, it is 
possible in most current mechanical ventilators to adjust 
the pressurization time and the expiratory cycling oﬀ 
criteria to better match the neural time with the venti-
lator time [15-18]. Costa and colleagues [19] examined 
the eﬀ ects of diﬀ erent pressurization times and diﬀ erent 
Figure 2. Flow chart of the studies analyzed. NIV, non-invasive ventilation.
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expiratory cycling criteria during PSV delivered by 
helmet or face mask. Th e ventilator inspiratory time was 
signiﬁ cantly longer with the face mask compared to the 
helmet. Th e helmet presented a signiﬁ cantly longer 
inspira tory and shorter expiratory trigger delay. However, 
a shorter pressurization time compared to a longer or 
intermediate time resulted in a signiﬁ cant improvement 
in patient ventilator synchrony.
To ameliorate the asynchrony that can be present with 
conventional pneumatic ventilator triggering, neural 
triggering using diaphragm electrical activity has been 
developed [20]. Moerer and colleagues [21] compared 
neurally and pneumatically triggered PSV delivered with 
a helmet with regard to synchrony and patient comfort. 
Th e pneumatic trigger was delayed compared to the 
neural trigger and directly increased with the level of 
PSV; during pneumatic triggering the number of wasted 
eﬀ orts increased with high PSV, while wasted inspiratory 
eﬀ orts did not occur during neural triggering. Th e 
expiratory delay was always lower with pneumatic com-
pared to neural triggering. Comfort of breathing was also 
lower during pneumatic triggering compared to neural 
triggering.
Humidity and noise
Although the optimal level of humidiﬁ cation of inspired 
gases during NIV is unknown, inadequate humidiﬁ cation 
can cause patient distress and favour intolerance [1,22, 
23]. Similar to CO2 rebreathing related to the helmet’s 
high internal volume, the humidity of expired gases can 
Table 1. Summary of the physiological studies
 Type of
 non-invasive Number
Source ventilation of subjects Interface Control Results
Patroniti et al. (2003) [7] CPAP 8 Helmet FM Higher CO2 rebreathing with helmet
Taccone et al. (2004) [8] CPAP 8 Helmet FM Higher CO2 rebreathing with helmet
Patroniti et al. (2007) [9] CPAP 5 Helmet with 
and without 
antisuff ocation valve 
- CO2 rebreathing limited by safety valve
Milan et al. (2011) [10] CPAP 5 Helmet with 
antisuff ocation valve
- CO2 rebreathing decreased by a higher 
diameter of safety valve
Costa et al. (2005) [11] PSV 8 Helmet - CO2 rebreathing not aff ected by 
PEEP on PSV level; inspiratory eff ort 
decreased, increasing the PSV
Racca et al. (2008) [13] PSV - CPAP 10 Helmet - Lower CO2 rebreathing with open 
circuit mechanical ventilators
Chiumello et al. (2003) [14] PSV - CPAP 6 Helmet FM Similar breathing pattern and WOB 
during CPAP, higher reduction of WOB 
during PSV with FM
Racca et al. (2005) [12] PSV 6 Helmet FM Higher CO2 rebreathing, inspiratory 
eff ort, autocycled breaths and 
dyspnea score with helmet during 
respiratory muscle load
Costa et al. (2010) [19] PSV diff erent 
inspiratory-expiratory 
cycling criteria
8 Helmet FM Shorter ventilator inspiratory time 
and longer with inspiratory-expiratory 
delay with helmet. The fast setting 
ameliorated patient-ventilator 
interaction
Moerer et al. (2008) [21] PSV pneumatically 
versus neurally 
triggered
7 Helmet - Shorter inspiratory-expiratory delays, 
lower wasted eff orts and better 
comfort with neurally triggered PSV
Chiumello et al. (2008) [24] CPAP 10 Helmet - Higher temperature and humidity 
of inspired gas compared to un-
humidifi ed medical gases
Cavaliere et al. (2003) [25] PSV 10 Helmet FM Higher acoustic compliance with 
helmet
CO2, carbon dioxide; CPAP, continuous positive airway pressure; FM, face mask; PSV, pressure-support ventilation; WOB, work of breathing.
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mix with the fresh inspired gases, which are more dry 
and cold, thus increasing the level of heat and humidity, 
avoiding the necessity of active humidiﬁ cation. Chiumello 
and colleagues [24] reported that during continuous ﬂ ow 
CPAP without an active humidiﬁ er, the temperature and 
humidity levels of the inspired gases were signiﬁ cantly 
higher compared to non-humidiﬁ ed medical gases and 
they were directly dependent on the gas ﬂ ow passing 
throught the helmet.
Compared to the face mask the helmet can expose the 
entire head to positive pressure, which may injure the 
tympanic membranes. Cavaliere and colleagues [25] 
evaluated the performance of the middle ear by recording 
the tympanometry and the acoustic reﬂ ex after one hour 
of PSV with both the helmet and the face mask. During 
PSV with the helmet, the tympanometry showed a slight 
increase in acoustic compliance but returned to basal 
values after one hour, while it did not show a change with 
the face mask. In both groups the acoustic reﬂ ex did not 
change. Th ese data may suggest the use of ear plugs in 
selective cases, such as during long-term use and when 
high airway pressures are used.
Clinical studies
Acute cardiogenic pulmonary edema
During acute pulmonary edema the main beneﬁ cial 
eﬀ ects of NIV besides the improvement of gas exhange 
are the reduction of preload and afterload, which im-
proves the cardiac performace [26,27].
In an observational study of 121 patients with pre-
sumed acute pulmonary cardiogenic edema, Foti and 
colleagues [28], in a prehospital setting applying a con-
tinous ﬂ ow CPAP with a helmet, found a signiﬁ cant 
improve ment in arterial oxygen saturation (79  ±  12% 
versus 97 ± 3%, P < 0.01) and in hemodynamics (systolic 
blood pressure 175 ± 49 mmHg versus 145 ± 28 mmHg, 
P  <  0.01). Th e helmet CPAP was well tolerated in all 
enrolled patients.
In a prospective pilot study with a matched control 
group of patients with hypoxemic acute respiratory 
failure related to cardiogenic pulmonary edema, Tonnelier 
and colleagues [29] reported that helmet CPAP signi-
ﬁ cantly reduced respiratory rate and heart rate and 
improved oxygenation (158  ±  94  mmHg versus 
145  ±  28  mmHg), similar to the mask. Control patients 
were selected from a group of patients with acute 
respiratory failure due to cardiogenic pulmonary edema 
treated with a facial mask. Th e helmet allowed a longer 
period of CPAP without any adverse event and good 
tolerance.
Hypoxemic acute respiratory failure
In a large multicenter survey of patients with hypoxemic 
acute respiratory failure, NIV was successful in avoiding 
intubation in 70% of the patients [30]. Patients with a 
high severity score (simpliﬁ ed acute physiology score 
(SAPS) II >34), older age, acute respiratory distress syn-
drome or pneumonia, severe metabolic acidosis, severe 
hypoxemia (partial pressure of oxygen in arterial blood 
(PaO2)/fraction of inspired oxygen (FiO2) <170) or failure 
in improvement in PaO2/FiO2 after one hour of treatment 
were at higher risk of failure [31].
In a matched control study, Antonelli and colleagues 
[32] evaluated the eﬃ  ciency of PSV delivered by helmet 
or face mask in patients with hypoxemic acute respiratory 
failure. Both groups had a similar improvement in oxy-
genation within the ﬁ rst hour; however, at support 
discontinuation the increase in oxygenation was higher 
for patients who received PSV by helmet (267 ± 104 mmHg 
versus 224 ± 81 mmHg, P < 0.05). Th e total duration of 
PSV was similar (40 ± 30 hours versus 42 ± 31 hours), as 
well as the intubation rate and hospital mortality. No 
patients in the helmet group compared to 38% of the 
mask group had intolerance to NIV.
Th e application of periodic deep insuﬄ  ation (sighs) 
during invasive mechanical ventilation may improve gas 
exchange [33-35]. In a prospective cross-over study, 
Cammarota and colleagues [36] found that during CPAP 
with either the helmet or face mask, the sigh (that is, an 
increase of airway pressure from 10 to 20  cmH2O for 
8 seconds every minute) signiﬁ cantly improved the arterial 
oxygenation and reduced the respiratory rate. Independent 
of sigh, the helmet CPAP group had higher oxygenation 
while the tolerance was similar in the two groups.
Similarly to the previous study [36], in hypoxemic acute 
respiratory failure Isgrò and colleagues [37], applying a 
periodic sigh or two CPAP levels (similar to bi-level 
positive airway pressure (BIPAP) ventilation) during con-
tinuous ﬂ ow CPAP with a helmet, found a signiﬁ cant 
improvement in oxygenation compared to basal CPAP 
(109.2  ±  33.9  mmHg versus 124.5  ±  45.2  mmHg and 
128  ±  52  mmHg). Th ere was no signiﬁ cant diﬀ erence 
between sigh and BIPAP regarding oxygenation levels.
Compared to PSV, neurally adjusted ventilatory assist 
(NAVA) improved ventilator synchrony in healthy sub-
jects [21]. Cammarota and colleagues [38] evaluated the 
short-term physiologic eﬀ ects of NAVA compared to 
PSV delivered with helmet in postextubation acute 
respiratory failure. NAVA signiﬁ cantly increased the 
ventilator inspiratory and reduced expiratory time. No 
asynchrony was present with NAVA, while there were no 
diﬀ erences in gas exchange and respiratory rate.
Immunocompromised patients
Th e respiratory complications in immuncompromised 
patients remain the main cause of morbidity and mor-
tality; thus, respiratory support that avoids or reduces 
pulmonary complications could be useful [39,40].
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Principi and colleagues [41], in a prospective clinical 
study of hematological malignancy patients with hypoxe-
mic acute respiratory failure compared to historical 
matched controls, observed that no patient failed helmet 
CPAP due to intolerance of the technique compared to 
11.4% of patients in the mask group, and that helmet 
CPAP could be applied continuously over a much longer 
period of time than mask CPAP (28.4 ± 0.2 hours versus 
7.5 ± 0.4 hours, P < 0.001). Th e oxygenation improvement 
was equal in the two groups but the intubation and 
mortality rates were lower with the helmet (0 versus 41% 
and 23 versus 47%, P < 0.001).
Rocco and colleagues [42], in a matched controlled 
study of immunocompromised patients of diﬀ erent etio-
logies of acute respiratory failure, showed that patients 
receiving PSV with helmet had signiﬁ cantly lower NIV 
discontinuations in the ﬁ rst 24 hours than patients 
treated with mask; also, fewer complications related to 
device were reported (that is, skin necrosis, P  =  0.01). 
Oxygenation, intubation and mortality rates were similar 
(202  ±  61  mmHg versus 224  ±  111  mmHg, 37% versus 
47%, and 47% versus 31%, respectively).
In an observational study of immunocompromised 
patients with acute respiratory failure, Rabitsch and 
colleagues [43] reported that helmet PSV signiﬁ cantly 
improved arterial oxygenation and respiratory rate, and 
only two patients (20%) were intubated.
Community-acquired pneumonia
Severe community-aquired pneumonia with intensive 
care admission and associated hypoxemic acute respira-
tory failure can require respiratory support in up of 60% 
of patients [44]. Carron and colleagues [45], in a pros-
pective observational study including 64 consecutive 
patients with acute respiratory failure due to community-
aquired pneumonia, investigated the failure of NIV. NIV 
was delivered as PSV with helmet. It was found that NIV 
succeeded in 43% of patients and failed in 56%. Th e only 
two independent factors associated with failure were 
changes in arterial oxygenation and oxygenation index 
between admission and after 1 hour of NIV.
In a large multicenter randomized controlled trial in 
patients with hypoxemic acute respiratory failure due to 
community-aquired pneumonia, Cosentini and colleagues 
[46] compared continuous ﬂ ow CPAP delivered by 
helmet and oxygen therapy for improving oxygenation. 
Th e primary end point was the time required to reach a 
PaO2/FiO2 ratio above 315 mmHg. Th is was reached in a 
signiﬁ cantly shorter time in the helmet group compared 
to the control group (1.5  hours versus 48  hours, 
P < 0.001). In the helmet group 95% of patients reached 
this end point compared to 30% of the controls 
(P  <  0.001). No patients required intubation or died 
during the study.
In the last recent pandemic due to inﬂ uenza A (H1N1) 
it was reported that patients admitted to intensive care 
for acute respiratory failure with severe hypoxemia 
required respiratory support in up of 80% of cases 
[47,48]. A retrospective observational study evaluated the 
use of NIV in all patients admitted to intensive care with 
presumed or conﬁ rmed inﬂ uenza A (H1N1) infection 
and hypoxemic acute respiratory failure [49]. NIV was 
delivered as CPAP and PSV with a helmet or face mask. 
Th ere was a signiﬁ cant improvement in gas exchange and 
respiratory and heart rates decreased. None of the 
patients required orotracheal intubation (100% success) 
and all the patients survived.
Postoperative surgery
Postoperative complications, which include atelectasis, 
pulmonary edema, postoperative pneumonia and acute 
respiratory failure, arise in 5% to 10% of all surgical 
patients and signiﬁ cantly increase morbidity and mor-
tality [1,50-52].
In a randomized, controlled, unblinded study, Squadrone 
and colleagues [53] showed that postoperative patients 
who developed hypoxemia and received helmet CPAP 
compared to those treated with oxygen alone had a better 
oxygenation and a lower intubation rate (1% versus 10%, 
P  =  0.005). Th e helmet group had a lower rate of 
pneumonia (2% versus 10%, P  =  0.02), infection (3% 
versus 10%, P = 0.03), and sepsis (2% versus 9%, P = 0.03), 
and spent fewer days in the ICU (1.4  ±  1.6 versus 
2.6 ± 4.2, P = 0.09) without any diﬀ erence in the hospital 
length of stay (15 ± 13 versus 17 ± 15, P = 0.10) .
In a matched-control study, Conti and colleagues [54] 
also found that in patients with acute respiratory failure 
after major abdominal surgery, PSV delivered by a helmet 
signiﬁ cantly improved oxygenation and reduced intuba-
tion rate (20% versus 48%, P = 0.036) compared to PSV 
with facial mask. Th e complications (mask intolerance, 
major leaks and ventilator-associated pneumonia) were 
signiﬁ cantly lower in the helmet group compared to the 
face mask group (12% versus 32%, P = 0.06).
In a prospective observational study evaluating helmet 
CPAP in postoperative patients who developed acute 
hypoxemic respiratory failure, Redondo-Calvo [55] and 
colleagues found that 74.7% of the patients did not 
require intubation. Th e intubated patients presented 
higher levels of illness and lower improvement in oxy-
genation and CPAP duration. Th e intubated patients had 
a longer hospital stay and higher rate of hospital deaths 
compared to unintubated (30.2  ±  20.1  days versus 
12.7 ± 8.2 days, P < 0.001, and 44% versus 15%, P = 0.004).
Although the NIV is commonly used to treat acute 
respiratory failure in postoperative patients, it has also 
been used to prevent acute respiratory complications 
after surgery [50]. Barbagallo and colleagues [56] 
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randomized 50 patients after elective lung resection to a 
prophylactic continuous ﬂ ow CPAP with helmet for two 
hours or to oxygen therapy. Th e helmet group had signiﬁ -
cantly higher oxygenation without any diﬀ erence in 
postoperative complications and mortality.
Hypercapnic acute respiratory failure
In COPD patients, NIV is recommended to improve gas 
exchange, and to decrease respiratory workload and the 
need for tracheal intubation [1,4].
In a cohort study, Antonelli and colleagues [57] evalu-
ated the eﬀ ect of PSV delivered by helmet or by face 
mask on gas exchange and intubation rate in COPD 
patients with acute exacerbation. After one hour both 
groups presented a signiﬁ cant reduction of partial 
pressure of carbon dioxide in arterial blood (PaCO2) and 
improvement in pH. However, the decrease in PaCO2 was 
lower in the helmet group compared to the face mask 
group (75 ± 15 mmHg versus 66 ± 15 mmHg, P = 0.01). 
Also, on discontinuing support, PaCO2 was higher 
(P = 0.002) and pH lower (P = 0.02) in the helmet group. 
Th e improvements in oxygenation and respiratory rate 
were similar as well as the intubation rate (30% versus 
42%). Intensive care and hospital mortality were not 
diﬀ erent between the groups.
Antonaglia and colleagues [58] ventilated a series of 
patients with severe exacerbation of COPD using PSV 
delivered by face mask for two hours; subsequently, only 
those in whom gas exchange improved were randomized 
to helmet or face mask. After four hours of NIV, the face 
mask group had a signiﬁ cantly lower PaCO2 compared to 
the helmet group (63 ± 14 mmHg versus 70 ± 4 mmHg, 
P = 0.01) with no diﬀ erence in oxygenation or respiratory 
rate. However, 9 of the 20 patients (45%) in the mask 
group compared to 2 of 20 (5%) in the helmet group 
required intubation (P < 0.01).
In a small group of hypercapnic patients with severe 
COPD recovering from acute exacerbation, Navalesi and 
colleagues [59] evaluated PSV delivered by a helmet or 
face mask in random order. Compared to spontaneous 
breathing, NIV reduced PaCO2 with both devices (from 
55.9  ±  7.3  mmHg to 52.0  ±  7.1  mmHg with helmet, 
P < 0.05; and from 55.5 ± 7.7 mmHg to 51.7 ± 8.5 mmHg 
with face mask, P  <  0.05). Ineﬀ ective inspiratory eﬀ orts 
were signiﬁ cantly more common with the helmet and 
although the WOB decreased to a similar extent as for 
spontaneous breathing, with the helmet the delay 
between inspiratory eﬀ ort and ventilator support was 
signiﬁ cantly longer.
Interfaces
In a prospective cross-over study Vargas and colleagues 
[60], in a group of patients at high risk for respiratory 
distress, compared three diﬀ erent NIV settings: PSV 
delivered by face mask; PSV at the same pressure support 
and PEEP with helmet; and PSV with 50% increases in 
pressure support and PEEP with helmet. At the same 
level of pressure support the helmet had a low inspiratory 
eﬀ ort compared to face mask. Th e increase of PSV 
reduced the inspiratory eﬀ ort to a similar extent as with 
the face mask. Patient ventilator asynchrony was more 
frequent with the helmet, while respiratory rate and 
patient comfort were similar among the three conditions.
Novel indications
Arterial oxygenation lower than 75  mmHg with an 
oxygen fraction higher than 50% is considered a contra-
indication to ﬁ beroptic bronchoscopy [61]. Antonelli and 
colleagues [62] investigated the feasibility and safety of 
ﬁ beroptic bronchoscopy with bronchoalveolar lavage 
during NIV delivered with a helmet in patients with acute 
respiratory failure. Oxygenation did not change through-
out the procedure and dropped only 2% at the end of the 
ﬁ beroptic bronchoscopy. No patients required sedatives 
or analgesics.
Sedation
Similar to invasive mechanical ventilation, sedation has 
been advocated to improve NIV tolerance and reduce the 
rate of failure [63,64].
In a prospectively uncontrolled study, Rocco and 
colleagues [65] evaluated the continuous infusion of 
remifentanil in patients with hypoxemic acute respiratory 
failure during NIV with helmet or mask. Th e mean 
remifentanil dose administered was 0.07  ±  0.03  μg/kg/
minute and infusion lasted 52 ± 10 hours in the success 
group. Th irty-six patients were enrolled and 22 (61%) 
continued NIV treatment; after one hour respiratory rate 
decreased and oxygenation increased with both helmet 
and face mask. Fourteen patients failed (39%) and 
required endotracheal intubation because of persistence 
of discomfort.
Discussion
In this review we identiﬁ ed, among the 33 studies 
considered, only 9 clinical studies in which the helmet 
was compared to face mask. Th e helmet presented 
similar oxygenation rates in eight [29,41,42,49,54,57-59] 
and similar intubation rates in four [32,42,57,59] of these 
compared to the face mask. Th e outcome was similar in 
six studies [32,42,54,57-59]. Th e tolerance was better 
with helmet in six of these studies [58,32,57,54,41,42].
Th e main application of NIV with helmet was for acute 
cardiogenic pulmonary edema, hypoxemic acute respira-
tory failure, community-acquired pneumonia, hypercapnic 
acute respiratory failure, and in post-operative and 
immunocompromised patients. Th e main favourable 
characteristics of the helmet (Table  3), such as low 
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distensibility, absence of any contact with the face, 
minimum presence of air leaks, the possibility to deliver 
continous ﬂ ow CPAP as well as non-invasive positive 
pressure ventilation, can extend the application of NIV in 
patients with acute respiratory failure. However, the high 
internal volume can promote higher CO2 rebreathing, 
patient ventilator asynchrony and lower reductions in 
WOB compared to the face mask. Higher levels of 
pressure support and faster pressurization rates, however, 
could improve the eﬃ  ciency of the helmet to be 
comparable to the face mask. Table 4 summarizes general 
recommendations to optimize NIV with the helmet.
Conclusion
Th e helmet has been shown to be an eﬀ ective interface 
for the application of NIV, but compared to the face mask 
it may increase patient ventilator asynchrony and CO2 
rebreathing. However, the helmet is better tolerated, 
allowing longer use. Further studies are required to 
deﬁ ne the ideal patient populations and open up new 
clinical indications for NIV with the helmet.
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